GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 651.88% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 06/05/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/17/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/16/2023 | 651.88% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 04/03/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/31/2023 | 651.88% | EF Hutton | → $2 | Reiterates | → Hold |
| 01/05/2023 | 651.88% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 1779.69% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 9298.46% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 7794.71% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 9298.46% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 06/05/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 05/17/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 05/16/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 04/03/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | → 购买 |
| 03/31/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | → 按住 |
| 01/05/2023 | 651.88% | EF Hutton | → 2 美元 | 启动覆盖开启 | → 按住 |
| 09/13/2022 | 1779.69% | HC Wainwright & Co. | 25 美元 → 5 美元 | 维护 | 购买 |
| 05/24/2021 | 9298.46% | HC Wainwright & Co. | → 25 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 4 月 13 日 | 7794.71% | B. 莱利证券 | → 21 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 3 月 17 日 | 9298.46% | 罗斯资本 | → 25 美元 | 启动覆盖开启 | → 购买 |
What is the target price for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的目标价格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by EF Hutton on August 7, 2023. The analyst firm set a price target for $2.00 expecting GTBP to rise to within 12 months (a possible 651.88% upside). 8 analyst firms have reported ratings in the last year.
EF Hutton于2023年8月7日公布了GT Biopharma（纳斯达克股票代码：GTBP）的最新目标股价。这家分析公司将目标股价定为2.00美元，预计GTBP将在12个月内升至12个月内（可能上涨651.88％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for GT Biopharma (GTBP)?
分析师对GT Biopharma（GTBP）的最新评级是多少？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by EF Hutton, and GT Biopharma reiterated their hold rating.
GT Biopharma（纳斯达克股票代码：GTBP）的最新分析师评级由EF Hutton提供，GT Biopharma重申了他们的持仓评级。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与GT Biopharma的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。GT Biopharma的最后一次评级是在2023年8月7日提交的，因此您应该预计下一个评级将在2024年8月7日左右公布。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析师对 GT Biopharma (GTBP) 的评级正确吗？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $2.00. The current price GT Biopharma (GTBP) is trading at is $0.27, which is within the analyst's predicted range.
尽管评级是主观的，而且会发生变化，但最新的GT Biopharma（GTBP）评级得到了重申，目标股价为0.00美元至2.00美元。GT Biopharma（GTBP）目前的交易价格为0.27美元，在分析师的预测区间内。